1. Which feature primarily distinguishes an experimental study from an observational study?
A. Presence of a control group
B. Large sample size
C. Manipulation of exposure by the investigator
D. Long follow-up period
Answer: C
2. Which of the following is considered the gold standard for evaluating the effectiveness of a medical intervention?
A. Cross-sectional study
B. Case-control study
C. Cohort study
D. Randomized Controlled Trial (RCT)
Answer: D
3. Clinical trials are mainly designed to evaluate the:
A. Prevalence of disease
B. Incidence of disease
C. Efficacy and safety of interventions
D. Distribution of risk factors
Answer: C
4. Which of the following is an example of an experimental study design?
A. Ecological study
B. Case-control study
C. Cohort study
D. Clinical trial
Answer: D
5. In a clinical trial, the investigator primarily manipulates:
A. Outcome
B. Exposure or intervention
C. Disease status
D. Confounding variables
Answer: B
6. The principal objective of a therapeutic clinical trial is to:
A. Estimate disease prevalence
B. Assess the effectiveness of a treatment
C. Measure incidence
D. Study disease distribution
Answer: B
7. Which of the following interventions can be evaluated using clinical trials?
A. New drugs
B. Vaccines
C. Medical devices
D. All of the above
Answer: D
8. Clinical trials are considered superior to observational studies because they:
A. Eliminate all bias completely
B. Allow manipulation of exposure under controlled conditions
C. Do not require follow-up
D. Never require statistical analysis
Answer: B
9. Which statement regarding clinical trials is CORRECT?
A. Exposure occurs naturally.
B. Participants choose their own intervention.
C. The investigator assigns the intervention.
D. Only healthy volunteers participate.
Answer: C
10. A randomized controlled trial is best described as:
A. A retrospective observational study
B. A planned prospective experiment
C. A prevalence survey
D. A descriptive study
Answer: B
11. Which of the following BEST defines a therapeutic clinical trial?
A. Evaluates disease prevalence
B. Compares a new treatment with the current standard treatment
C. Measures vaccine coverage
D. Estimates incidence density
Answer: B
12. Participants in a therapeutic clinical trial generally have:
A. No disease
B. The disease under investigation
C. Unknown disease status
D. Genetic disorders only
Answer: B
13. Which group usually receives the standard treatment in a clinical trial?
A. Experimental group
B. Intervention group
C. Control (Comparator) group
D. Randomization group
Answer: C
14. In therapeutic trials, outcomes are compared because investigators expect the new treatment to:
A. Be identical to the standard treatment
B. Be inferior to the standard treatment
C. Produce better clinical outcomes
D. Increase disease incidence
Answer: C
15. Clinical trials are generally:
A. Retrospective
B. Cross-sectional
C. Prospective
D. Ecological
Answer: C
16. Which statement best explains why clinical trials have high internal validity?
A. Participants self-select treatment.
B. Exposure is controlled by investigators.
C. Disease occurs before exposure.
D. Participants are selected after outcome.
Answer: B
17. Which of the following is an example of a prevention trial?
A. Comparing two antihypertensive drugs
B. Evaluating a new vaccine against influenza
C. Measuring hypertension prevalence
D. Comparing smokers and non-smokers
Answer: B
18. Prevention trials usually enroll:
A. Patients already having the disease
B. Individuals susceptible to developing the disease
C. Hospitalized patients only
D. Only children
Answer: B
19. Which comparator is commonly used in vaccine prevention trials?
A. Relative Risk
B. Odds Ratio
C. Placebo
D. Incidence Density
Answer: C
20. Which outcome is expected if a preventive vaccine is effective?
A. Higher disease occurrence in the vaccine group
B. Equal disease occurrence in both groups
C. Lower disease occurrence in the vaccinated group
D. Increased prevalence
Answer: C
21. The most critical methodological feature of a randomized controlled trial is:
A. Follow-up
B. Randomization
C. Census
D. Matching
Answer: B
22. Randomization primarily ensures that:
A. Participants choose their treatment.
B. Investigators assign treatment according to preference.
C. Every participant has an equal chance of receiving any intervention.
D. Only healthy individuals are enrolled.
Answer: C
23. Which of the following is the PRIMARY purpose of randomization?
A. Increase sample size
B. Reduce confounding and selection bias
C. Eliminate the need for follow-up
D. Increase prevalence
Answer: B
24. Which statement regarding randomization is FALSE?
A. It is performed before follow-up begins.
B. It balances known and unknown confounders.
C. Participants decide which treatment they receive.
D. It improves comparability between study groups.
Answer: C
25. Which statement BEST summarizes randomized controlled trials?
A. Participants are selected according to disease status, randomly assigned to intervention or comparator groups, followed prospectively, and outcomes are compared to determine the efficacy and safety of the intervention.
B. Participants are selected according to exposure history only.
C. Participants are selected after outcome occurrence.
D. Exposure occurs naturally without investigator involvement.
Answer: A
26. The primary purpose of randomization in a clinical trial is to:
A. Increase sample size
B. Ensure equal follow-up time
C. Create comparable study groups and minimize bias
D. Reduce study cost
Answer: C
27. Which of the following is NOT a benefit of randomization?
A. Balances known confounders
B. Balances unknown confounders
C. Eliminates all measurement errors
D. Reduces selection bias
Answer: C
28. In a randomized clinical trial, allocation of participants to treatment groups should ideally be done by:
A. The participant
B. The treating physician
C. A neutral random allocation process
D. The hospital administrator
Answer: C
29. Which statement best explains why participants should not choose their treatment group?
A. It increases sample size.
B. It introduces selection bias.
C. It reduces follow-up.
D. It decreases statistical power.
Answer: B
30. Which type of bias is primarily prevented by randomization?
A. Recall bias
B. Selection bias
C. Publication bias
D. Lead-time bias
Answer: B
31. In a randomized controlled trial, the control group usually receives:
A. No intervention under any circumstances
B. The currently accepted standard treatment or placebo (when appropriate)
C. A higher dose of the new drug
D. Another experimental drug only
Answer: B
32. Which of the following best describes single blinding?
A. Only the investigator is unaware of treatment allocation.
B. Only the participant is unaware of treatment allocation.
C. Both participant and investigator are unaware.
D. Participant, investigator, and analyst are unaware.
Answer: B
33. In a double-blind clinical trial:
A. Only participants are blinded.
B. Only investigators are blinded.
C. Both participants and investigators are unaware of treatment allocation.
D. Only statisticians are blinded.
Answer: C
34. In a triple-blind clinical trial, who remains blinded?
A. Participant only
B. Participant and investigator
C. Participant, investigator, and data analyst
D. Ethics committee only
Answer: C
35. The principal purpose of blinding is to:
A. Increase sample size
B. Reduce subjective bias in outcome assessment
C. Improve randomization
D. Shorten follow-up
Answer: B
36. Which of the following is MOST likely to occur if participants know they are receiving a new drug?
A. Randomization bias
B. Reporting bias due to altered symptom reporting
C. Attrition bias only
D. Ecological fallacy
Answer: B
37. Which type of bias is minimized when investigators are blinded?
A. Observer (assessment) bias
B. Recall bias
C. Selection bias
D. Publication bias
Answer: A
38. Blinding is particularly useful because it reduces:
A. Random error only
B. Bias in outcome assessment
C. Sample size requirements
D. Disease incidence
Answer: B
39. Which of the following is an example of co-intervention?
A. Random assignment to treatment groups
B. Participants in one group using additional therapy outside the trial
C. Statistical adjustment for confounding
D. Loss to follow-up
Answer: B
40. Co-intervention mainly threatens the:
A. Internal validity of the trial
B. External validity only
C. Sample size calculation
D. Disease prevalence
Answer: A
41. Which statement regarding placebo is CORRECT?
A. It is always superior to standard treatment.
B. It is an inactive intervention used as a comparator when ethically appropriate.
C. It contains the active ingredient at a lower dose.
D. It is used only in Phase IV trials.
Answer: B
42. In vaccine trials, the placebo group is followed mainly to compare:
A. Mortality only
B. Disease occurrence and adverse events
C. Disease prevalence
D. Incidence density only
Answer: B
43. A new antihypertensive drug is compared with the currently recommended medication rather than placebo. The current medication acts as the:
A. Experimental intervention
B. Standard comparator (active control)
C. Randomization factor
D. Confounder
Answer: B
44. Which characteristic is essential for maintaining blinding in drug trials?
A. Different colors and shapes of tablets
B. Identical appearance of interventions
C. Participants choosing treatment
D. Open-label allocation
Answer: B
45. Which of the following is the BEST example of a therapeutic clinical trial?
A. Testing a malaria vaccine in healthy volunteers
B. Comparing two chemotherapy regimens in cancer patients
C. Measuring hypertension prevalence
D. Conducting a household health survey
Answer: B
46. Which of the following is the BEST example of a prevention trial?
A. Comparing insulin regimens in diabetic patients
B. Testing a new influenza vaccine in healthy adults
C. Studying smoking prevalence
D. Evaluating disease survival
Answer: B
47. In a therapeutic clinical trial, the primary outcome is usually:
A. Disease prevalence
B. Improvement, recovery, or reduction in disease severity
C. Population incidence
D. Census data
Answer: B
48. Which of the following is TRUE regarding follow-up in clinical trials?
A. Participants are assessed only once.
B. Outcomes are evaluated prospectively at predefined intervals.
C. Follow-up is unnecessary after randomization.
D. Only the intervention group is followed.
Answer: B
49. A vaccine trial reports significantly fewer infections in the vaccinated group compared with the placebo group. This finding suggests:
A. The vaccine is ineffective.
B. The vaccine demonstrates preventive efficacy.
C. Randomization failed.
D. Selection bias occurred.
Answer: B
50. Which statement BEST summarizes the methodological strengths of randomized controlled trials?
A. Randomization, appropriate control groups, blinding, and prospective follow-up together minimize bias and provide the highest level of evidence for evaluating medical interventions.
B. They eliminate all sources of bias completely.
C. They are useful only for drug studies.
D. They measure disease prevalence only.
Answer: A
51. Phase I clinical trials are primarily conducted to evaluate:
A. Effectiveness
B. Safety and tolerability
C. Cost-effectiveness
D. Population coverage
Answer: B
52. Phase I clinical trials are usually conducted in:
A. Thousands of patients
B. Healthy volunteers
C. Patients with advanced disease only
D. Community populations
Answer: B
53. Approximately how many participants are generally included in a Phase I clinical trial?
A. Up to 50
B. 100–500
C. 1,000–5,000
D. More than 10,000
Answer: A
54. The primary objective of Phase II clinical trials is to evaluate:
A. Post-marketing surveillance
B. Long-term safety, dose, and preliminary efficacy
C. Community effectiveness only
D. Population prevalence
Answer: B
55. Phase II clinical trials usually include approximately:
A. Up to 50 participants
B. 100–500 participants
C. More than 5,000 participants
D. Community-wide samples
Answer: B
56. Which phase is mainly designed to establish the effectiveness (efficacy) of an intervention?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: C
57. Phase III clinical trials usually involve:
A. Healthy volunteers only
B. Hundreds to thousands of participants at risk or with disease
C. Laboratory animals
D. Small pilot groups
Answer: B
58. Which phase is conducted after regulatory approval and marketing?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: D
59. Phase IV clinical trials are also known as:
A. Pilot trials
B. Screening trials
C. Post-marketing surveillance studies
D. Feasibility studies
Answer: C
60. Which phase is MOST likely to detect rare adverse drug reactions?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: D
61. Which sequence correctly represents the phases of clinical trials?
A. Safety → Long-term safety & dose → Effectiveness → Post-marketing surveillance
B. Effectiveness → Safety → Dose → Surveillance
C. Dose → Safety → Surveillance → Effectiveness
D. Surveillance → Safety → Dose → Effectiveness
Answer: A
62. Which clinical trial phase is MOST concerned with determining the optimal dose of a new drug?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: B
63. Which statement regarding Phase III trials is TRUE?
A. They are performed only in healthy volunteers.
B. They compare the new intervention with the standard treatment under controlled conditions.
C. They are performed after marketing.
D. They are laboratory studies.
Answer: B
64. Regulatory approval of a new drug generally occurs after successful completion of:
A. Phase I only
B. Phase II only
C. Phase III trials
D. Phase IV trials
Answer: C
65. Which of the following BEST describes post-marketing surveillance?
A. Evaluation before human use
B. Monitoring safety after widespread clinical use
C. Animal experimentation
D. Laboratory toxicity testing
Answer: B
66. A pharmaceutical company wants to determine whether a new HIV regimen improves viral load reduction compared with standard HAART. Which type of clinical trial is MOST appropriate?
A. Prevention trial
B. Therapeutic trial
C. Screening trial
D. Ecological study
Answer: B
67. Which outcome is commonly used in the HIV therapeutic trial example discussed in the lecture?
A. Blood glucose
B. Viral load and CD4 count
C. Blood pressure
D. Serum cholesterol
Answer: B
68. In a therapeutic trial, participants are randomized primarily to ensure:
A. Equal disease severity across groups as much as possible
B. Different follow-up periods
C. Different diagnostic criteria
D. Unequal sample sizes
Answer: A
69. Which of the following BEST represents the sequence in a therapeutic clinical trial?
A. Randomization → Screening → Outcome assessment
B. Screening → Eligibility → Randomization → Follow-up → Outcome assessment
C. Outcome assessment → Randomization → Treatment
D. Treatment → Screening → Randomization
Answer: B
70. Which of the following BEST describes a prevention trial?
A. Enrolling diseased patients to compare two therapies
B. Enrolling susceptible healthy individuals to evaluate preventive interventions
C. Estimating disease prevalence
D. Comparing hospital mortality
Answer: B
71. In a vaccine prevention trial, participants are usually selected because they are:
A. Already infected
B. Susceptible to developing the disease
C. Hospitalized
D. Receiving chemotherapy
Answer: B
72. In a vaccine prevention trial, the principal outcome measured is:
A. Cure rate
B. Disease occurrence after vaccination
C. Disease prevalence only
D. Hospital stay
Answer: B
73. Which of the following is MOST appropriate for comparing vaccine efficacy between vaccinated and placebo groups?
A. Measuring disease occurrence during follow-up
B. Measuring baseline prevalence only
C. Measuring incidence before vaccination
D. Comparing only laboratory values
Answer: A
74. Which statement regarding clinical trial phases is FALSE?
A. Phase I primarily evaluates safety.
B. Phase II evaluates dose and preliminary efficacy.
C. Phase III evaluates effectiveness.
D. Phase IV is conducted before regulatory approval.
Answer: D
75. Which statement BEST summarizes the progression of clinical trial phases?
A. Clinical trials progress systematically from safety assessment (Phase I) through dose optimization (Phase II), effectiveness evaluation (Phase III), and long-term post-marketing safety surveillance (Phase IV).
B. Every phase evaluates only efficacy.
C. Phase IV precedes Phase I.
D. Phase I is performed after licensing.
Answer: A
76. Which of the following is considered the highest level of evidence for evaluating the efficacy of a new medical intervention?
A. Case series
B. Cohort study
C. Case-control study
D. Randomized Controlled Trial (RCT)
Answer: D
77. A pharmaceutical company has developed a new antihypertensive drug. Before marketing approval, the drug is tested against the current standard therapy in 5,000 patients under controlled conditions. Which phase is this?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: C
78. A vaccine has already been licensed and is being monitored nationwide for rare neurological adverse events. Which phase of the clinical trial is being conducted?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: D
79. Which statement BEST explains why Randomized Controlled Trials are called the gold standard?
A. They are the cheapest studies.
B. They provide the highest level of evidence by minimizing bias and confounding.
C. They never require ethical approval.
D. They eliminate all errors completely.
Answer: B
80. Which of the following is the most important ethical requirement before enrolling participants into a clinical trial?
A. Statistical significance
B. Written informed consent
C. Randomization
D. Large sample size
Answer: B
81. A clinical trial compares a new antibiotic with the currently recommended antibiotic rather than a placebo because withholding treatment would be unethical. The current antibiotic serves as:
A. Placebo
B. Active comparator
C. Experimental intervention
D. Confounder
Answer: B
82. Which statement regarding placebo use is MOST appropriate?
A. Placebos should always replace effective treatment.
B. Placebos are acceptable only when ethically justified and no proven effective therapy is denied.
C. Every clinical trial must include a placebo.
D. Placebos are used only in Phase IV studies.
Answer: B
83. Which situation would MOST likely require a double-blind trial?
A. Comparing two surgical procedures with obvious differences
B. Comparing two tablets with identical appearance
C. Measuring disease prevalence
D. Conducting a census
Answer: B
84. Which of the following is the greatest advantage of double blinding?
A. Reduces sample size
B. Prevents selection bias
C. Minimizes participant and investigator assessment bias
D. Eliminates confounding completely
Answer: C
85. A participant receiving a placebo begins taking the investigational drug obtained from another participant. This is an example of:
A. Randomization
B. Co-intervention
C. Allocation concealment
D. Matching
Answer: B
86. Which methodological feature of RCTs primarily controls both known and unknown confounders?
A. Blinding
B. Randomization
C. Matching
D. Stratification
Answer: B
87. A researcher evaluates a new HIV treatment by comparing viral load reduction and CD4 count improvement with standard HAART. This trial is primarily assessing:
A. Diagnostic accuracy
B. Therapeutic efficacy
C. Disease prevalence
D. Screening effectiveness
Answer: B
88. A prevention trial demonstrates that vaccinated participants develop significantly fewer infections than those receiving placebo. Which conclusion is MOST appropriate?
A. The vaccine shows preventive efficacy.
B. The vaccine cures existing disease.
C. The placebo is superior.
D. The trial failed.
Answer: A
89. Which of the following BEST distinguishes therapeutic and prevention trials?
A. Therapeutic trials involve healthy individuals only.
B. Prevention trials enroll susceptible individuals, whereas therapeutic trials enroll patients with disease.
C. Both enroll identical populations.
D. Prevention trials never use randomization.
Answer: B
90. Which statement regarding follow-up in clinical trials is TRUE?
A. Participants are followed only until treatment begins.
B. Follow-up occurs prospectively according to a predefined schedule.
C. Follow-up is unnecessary in randomized trials.
D. Only the intervention group requires follow-up.
Answer: B
91. A researcher discovers that investigators assessing outcomes know which participants received the experimental treatment. Which bias is MOST likely?
A. Recall bias
B. Observer (assessment) bias
C. Attrition bias
D. Selection bias
Answer: B
92. Which of the following is LEAST likely to improve the internal validity of an RCT?
A. Randomization
B. Blinding
C. Standardized follow-up
D. Convenience sampling without eligibility criteria
Answer: D
93. Which is the major disadvantage of randomized clinical trials?
A. Cannot estimate treatment efficacy
B. Usually expensive and complex to conduct
C. Cannot minimize confounding
D. Cannot perform follow-up
Answer: B
94. Which factor most limits the generalizability (external validity) of clinical trial findings?
A. Participants are volunteers selected using strict eligibility criteria.
B. Randomization
C. Blinding
D. Prospective follow-up
Answer: A
95. Which statement regarding clinical trial participants is CORRECT?
A. Every patient with the disease is automatically eligible.
B. Participants are selected according to predefined inclusion and exclusion criteria.
C. Eligibility is determined after outcome assessment.
D. Participants are selected randomly from the general population.
Answer: B
96. Why are inclusion and exclusion criteria established before participant enrollment?
A. To increase prevalence
B. To ensure participant safety and improve study validity
C. To reduce randomization
D. To eliminate follow-up
Answer: B
97. Which of the following BEST describes internal validity in a clinical trial?
A. Ability to generalize results to all populations
B. Confidence that observed differences are due to the intervention rather than bias or confounding
C. Ability to recruit more participants
D. Ability to publish results
Answer: B
98. Which statement regarding external validity is TRUE?
A. It refers to how well the results can be generalized to other populations.
B. It measures statistical significance.
C. It is determined only by sample size.
D. It is identical to internal validity.
Answer: A
99. A clinical trial is scientifically well-designed but ethically unacceptable because informed consent was not obtained. Which principle has been violated?
A. Randomization
B. Autonomy
C. Blinding
D. Statistical power
Answer: B
100. Which statement BEST summarizes Randomized Controlled Trials?
A. Randomized Controlled Trials are prospective experimental studies in which investigators assign interventions, use randomization and often blinding to minimize bias, compare outcomes with appropriate control groups, evaluate efficacy and safety through different trial phases, and provide the strongest evidence for clinical decision-making despite being expensive, ethically challenging, and sometimes limited in generalizability.
B. Randomized Controlled Trials are retrospective observational studies.
C. Randomized Controlled Trials measure only disease prevalence.
D. Randomized Controlled Trials are useful only for drug evaluation.
Answer: A
